# Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

> **NCT04043455** · PHASE2 · TERMINATED · sponsor: **Arena Pharmaceuticals** · enrollment: 273 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Olorinab
- **DRUG:** Olorinab
- **DRUG:** Olorinab
- **DRUG:** Placebo
- **DRUG:** Olorinab
- **DRUG:** Olorinab

## Key facts

- **NCT ID:** NCT04043455
- **Lead sponsor:** Arena Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-24
- **Primary completion:** 2021-04-29
- **Final completion:** 2021-04-29
- **Target enrollment:** 273 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04043455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04043455, "Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04043455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*